Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03268993
Other study ID # 18-028
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 27, 2018
Est. completion date July 22, 2019

Study information

Verified date April 2023
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication. In this study, participants who have been curatively treatment for head and neck cancer, will take Avmacol twice a day for 3 months.


Description:

The broccoli seed preparation, Avmacol®, results in acute and/or sustained induction of NRF2 target gene transcripts in the oral mucosa of patients who have been curatively treated for a tobacco-related head and neck squamous cell carcinoma (HNSCC), including high grade dysplasia, carcinoma in situ, or invasive carcinoma. This study is not designed to examine the therapeutic or reparative effects of Avmacol® on premalignant lesions of the oral cavity. We will systematically assess the clinical chemopreventive potential of Avmacol® administration to patients with tobacco-related HNSCC at high risk for second primary tumor by: 1. Conducting this phase 0 clinical study to evaluate the pharmacodynamic range of NRF2 pathway activation in the oral mucosa of HNSCC patients, in response to two tolerable and bioactive doses of Avmacol®; 2. Determining whether the level of NRF2 pathway activation achieved in human oral epithelium is chemopreventive in the NQO1 murine model of environmental carcinogenesis; and 3. Analyzing specimens from the Phase 0 trial to determine whether Avmacol® induces changes in alternative biomarkers of SF chemopreventive efficacy identified in the laboratory.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date July 22, 2019
Est. primary completion date July 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participants must have completed curative-intent therapy (including surgery, radiation, and/or chemotherapy) for a first tobacco-related oral premalignant lesion (OPL) or HNSCC of any stage (eligible lesions include high grade dysplasia; carcinoma in situ; or stage I-IVa HNSCC). 2. Primary site may include oral cavity, pharynx, or larynx. Oropharynx primaries must be HPV (-) as defined by routine p16 IHC at the local site. 3. Participants may be enrolled between 3 months and 5 years AFTER completion of curative-intent therapy (including surgery, radiotherapy, and/or chemotherapy). 4. Participants may have untreated OPLs (i.e., hyperplasia, dysplasia, carcinoma in situ) at the time of study entry, provided the index OPL or HNSCC was definitively treated. 5. Participants must be at least 18 years old. 6. Participants must have a Karnofsky Performance Status of 80% or higher or an ECOG of 0-1 (Appendix A). 7. Current and former tobacco users are eligible. The tobacco use assessment form must be completed following consent, to assure eligibility (Appendix B). Patients must have =10 pack-year cumulative tobacco exposure or its equivalent to be eligible. This is defined as follows: 1. Cigarette exposure: =10 pack-years OR 2. Cigar exposure: = 10 cigar-years, where 1 cigar year is defined as having smoked on average = 1 cigar/day for a year OR 3. Chewing tobacco: =10 snuff-years, where 1 snuff year is defined as using on average = 1 pinch (dip) of chewing tobacco/day for a year. 8. Able to perform written, informed consent. 9. Women of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 Days prior to the first study intervention. 10. WCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation. Exclusion Criteria: 1. Participants have a history of another malignancy within 2 years prior to starting study treatment, except for excised and cured carcinoma-in-situ of breast or cervix; non-melanomatous skin cancer; T1-2, N0, M0 differentiated thyroid carcinoma either resected or under active surveillance; superficial bladder cancer; T1a or T1b prostate cancer comprising < 5% of resected tissue with normal prostate specific antigen (PSA) since resection, or status post external beam radiation or brachytherapy with normal PSA since radiation. 2. Primary oropharyngeal HNSCC which is HPV (+) as defined by p16 IHC. 3. Participants with acute intercurrent illness or those who had major surgery within the preceding 4 weeks unless they have fully recovered. 4. Participants who have a positive pregnancy test, are pregnant, or breast feeding. 5. Patients who are not practicing adequate contraception are ineligible if they are of child bearing potential. 6. Patients currently using anti-neoplastic or anti-tumor agents, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy. 7. Chronic anticoagulation with warfarin. Patients on low molecular weight heparin or fondaparinux may be enrolled. 8. Use of chronic prescribed medications which are potent inducers or inhibitors of CYP3A4 (Appendix C). 9. Chronic use of steroids at immunosuppressive doses. (Note, physiologic replacement doses of glucocorticoid or mineralocorticoid are acceptable, eg. prednisone 5-10 mg/day; fludrocortisone 0.1-0.2 mg/day.) 10. History of severe food intolerance to broccoli.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Avmacol
Avmacol is a dietary supplement available over the counter

Locations

Country Name City State
United States UPMC Eye Center - Eye and Ear Institute Pittsburgh Pennsylvania
United States UPMC Hillman Cancer Center Pittsburgh Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
University of Pittsburgh National Cancer Institute (NCI), University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in NRF2 target gene expression Quantitative changes in NRF2 target gene transcripts expression (i.e. NQO1 and GCLC) in oral mucosa (buccal cytobrush) by quantitative polymerase chain reaction (qPCR) according to a linear mixed model framework. From baseline throughout treatment period, up to 4 months
Secondary Change in NRF2 target proteins Changes in NRF2 target proteins in buccal punch biopsies by immunoblotting. From baseline throughout treatment period, up to 4 months
Secondary Change in NRF2 target gene transcripts Change in NRF2 target gene transcripts, between the two doses of Avmacol® by immunoblotting. From baseline throughout treatment period, up to 4 months
Secondary Change in NRF2-independent proteins Change in NRF2 target gene transcripts, between the two doses of Avmacol® by immunoblotting. From baseline throughout treatment period, up to 4 months
Secondary Alterations of Avmacol® activity in PBMCs - NK cells Changes in Peripheral Blood Mononuclear Cells (PBMC) gene expression and flow cytometry patterns in NK cells. From baseline throughout treatment period, up to 4 months
Secondary Alterations of Avmacol® activity in PBMCs - T cells Changes in Peripheral Blood Mononuclear Cells (PBMC) gene expression and flow cytometry patterns in T cells. From baseline throughout treatment period, up to 4 months
Secondary Change in serum cytokine levels Change in serum cytokine levels, as determined by multiplexed bead-based cytokine assays. From baseline throughout treatment period, up to 4 months
Secondary Measurement of serum albumin-bound SF Measurement of urinary metabolites of SF using isotope dilution mass spectrometry. From baseline throughout treatment period, up to 4 months
Secondary Safety profile in accordance with NCI CTCAE v.4 Patients will receive a diary for daily logging of adverse events. This will tabulated by Avmacol dose and type and grade of adverse events. The mean frequency and grade of events will be calculated by dose, and between-dose differences compared by means Throughout treatment period, up to 4 months
Secondary Proportion of patients primary tumors harboring genomic alteration of NRF2 related genes Genomic alterations in primary tumors will be characterized and the proportion determined by number of patients with NRF2 related genes per the total number of patients studied. At baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2